High SK1 expression contributes to immune checkpoint inhibitors (like anti-PD-1 or anti-CTLA-4) resistance in melanoma, and its inhibition enhances treatment response, making SK1 a potential therapeutic target [217]. The gene discussed is SPHK1; the disease is melanoma.